Curriculum vitae matthew ryan weir, M. D



Download 0.51 Mb.
Page2/7
Date conversion04.02.2017
Size0.51 Mb.
1   2   3   4   5   6   7
PUBLICATIONS - (REFEREED)


  1. Kirkman RL, Strom TB, Weir MR, Tilney NL. Late mortality and morbidity in recipients of long-term renal allografts. Transplantation 1982;34:347-351.

  2. Weir MR, Thornton GF. Extrapulmonary tuberculosis. Experience of a community hospital and review of the literature. American Journal of Medicine 1985;79:467-478.

  3. Weir MR, Kirkman RL, Strom, TB, Tilney NL. Liver disease in recipients of long-functioning renal allografts. Kidney International 1985;28:839-844.

  4. Shen SY, Weir MR, Kosenko A, Revie DR, Ordonez JV, Dagher FJ, Chretien P, Sadler JH. Reevaluation of T cell subset monitoring in cyclosporine-treated renal allograft recipients. Transplantation 1985;40:620-623.

  5. Shen SY, Weir MR, Litkowski LJ, Anthony RL, Welik RA, Kosenko A, Light PD, Dagher FJ, Sadler JH. Enzyme- linked immunosorbent assay for serum renal tubular antigen in kidney transplant patients. Transplantation 1985;40:642-647.

  6. Weir MR. Kirkman RL, Strom TB. Long-term effects of hepatitis B virus in renal transplant recipients: analysis of morbidity and mortality. Transplant Proc 1985;XVII:163-164.

  7. Weir MR, Hall-Craggs M, Shen SY, Posner JN, Alongi SV, Dagher FJ, Sadler JH. The prognostic value of the eosinophil in acute renal allograft rejection. Transplantation 1986;41:709-712.

  8. Weir MR, Irwin BC, Maters AW, Genemans G, Shen SY, Charache P, Williams GM. Incidence of cytomegalovirus disease in cyclosporine-treated renal transplant recipients based on donor/recipient pretransplant immunity. Transplantation 1987;43:187-193.

  9. Josselson J, Kyser BA, Weir MR, Sadler JH. Hepatitis B surface antigenemia in a chronic hemodialysis program: lack of influence on morbidity and mortality. AJKD 1987;9:456-461.

  10. Drusano GL, Weir MR, Forrest A, Plaisance K, Emm T, Standiford HC. Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function. Antimicrobial Agents and Chemotherapy 1987; 31:860-864.

  11. Shen SY, Weir MR, Revie DR, Dagher FJ, Bentley FR, Chretien PB, Sadler JH. Differentiation of acute rejection from acute cyclosporine nephrotoxicity in renal transplants peripheral T cell subset counts. Transplant Proc 1987; 19:1776-1779.

  12. Weir MR, Josselson J, Giard MJ, Warren JB, Posner JN, Lam YWF, Zaske DE, Saunders E. Sustained-release diltiazem compared with atenolol monotherapy for mild to moderate systemic hypertension. American Journal of Cardiology 1987; 60:36I-41I.

  13. Weir MR, Shen SY, Dagher FJ, Bentley FR, Lesko L, Sadler JH. Evaluation of the effects of cyclosporine and HLA-typed source leukocyte transfusions (apheresis by-products) on the immune systems of highly sensitized prospective renal allograft recipients. Transplant Proc 1987;19(1):735-737.

  14. Shen SY, Zemel SM, Weir MR, Dagher FJ, Bentley FR. Conversion of cyclosporine to azathioprine in renal transplant patients. Transplant Proc 1987;19:2032-2036.

  15. Zemel SM, Shen SY, Weir MR, Dagher FJ, Bentley FR. Effects of HLA matching and panel reactive antibodies in the development of rejection after conversion of cyclosporine to azathioprine. Transplant Proc 1987; 19:2029-2031.

  16. Weir MR, Irwin BC, Maters AW, Genemans G, Shen SY, Charache P, Williams GM. Morbid outcome of cytomegalovirus-negative transplant recipients receiving cytomegalovirus-positive kidneys. Transplant Proc 1987; 19:2137-2141.

  17. Plaisance K, Drusano G, Forrest A, Weir M, Standiford H. The effect of renal function on the bioavailability of ciprofloxacin. Clin Pharmacol Ther 1987; 41:195-200.

  18. Weir MR, Henry ML, Blackmore M, et al. Incidence and morbidity of cytomegalovirus disease associated with a seronegative recipient receiving seropositive donor-specific transfusion and living-related donor transplantation. A multi-center evaluation. Transplantation 1988;45:111-116.

  19. Weir MR, Saunders E. Pharmacologic management of systemic hypertension in blacks. American Journal of Cardiology 1988; 61:46H-52H.

  20. Weir MR, Sowers JR. Physiologic and hemodynamic considerations in blood pressure control while maintaining organ perfusion. American Journal of Cardiology 1988; 61:60H-66H.

  21. Forrest A, Weir MR, Plaisance KI, Drusano GL, Leslie J, Standiford HC. Relationships between renal function and disposition of oral ciprofloxacin. Antimicrobial Agents and Chemotherapy 1988; 32:1537-1540.

  22. Weir MR, Salomon DR, Cohen DJ, Carpenter CB. Lack of secondary suppressor response in enhanced allografted rats with endogenous suppressor activity in spleen and diminished cytotoxic T cell response. Transplantation 1988;46:731-739.

  23. Weir MR, Shen SY, Dagher FJ, Bentley FR, Lesko LJ, Sadler JH. Effects of allostimulation and cyclosporine therapy on cytotoxic antibody production in highly sensitized prospective renal transplant recipients. Transplantation 1988;46:591-594.

  24. Weir MR, Josselson J. Prevention of end-stage renal disease: a focus of antihypertensive therapy. Maryland Medical Journal 1988; 37:369-372.

  25. Weir MR, Peppler R, Gomolka D, Handwerger BS. Additive effect of cyclosporine and verapamil on the inhibition of activation and function of human peripheral blood mononuclear cells. Transplant Proc 1988; 20(Suppl 2):240-244.

  26. Weir MR, Krichten C, Urick A, Saunders E, Lavin PT. Comparison of enalapril and hydrochlorothiazide in mild hypertension and changes in plasma lipid concentrations during therapy. Clinical Therapeutics 1988; 10:712-724.

  27. Weir MR, Peppler R, Gomolka D, Handwerger BS. Additive inhibitory effect of cyclosporine and verapamil may occur through different mechanisms which may be dependent or independent of the slow calcium channel. Transplant Proc 1989; 21:866-870.

  28. Weir MR, Klassen DK, Shen SY, Sullivan D, Buddemeyer EU, Handwerger, BS. Acute effects of intravenous cyclosporine on renal function in healthy humans. Transplant Proc 1989; 21:915-917.

  29. Shen SY, Weir MR, Coughlin TR. Renal allograft biopsy and conversion from cyclosporine to azathioprine. Transplantation 1989;47:223-229.

  30. Weir MR, Klassen DK, Hoover N, Douglas FL. Preliminary observations of the acute effects of selective serum /thromboxane inhibition and angiotensin converting enzyme inhibition on blood pressure and renal hemodynamics in hypertensive humans. J Clin Pharmacol 1989;29:1108-1116.

  31. Weir MR. The effects of enalapril on blood pressure, renal hemodynamics, and renal function. Clin Ther 1989;11:685-700.

  32. Shen SY, Wood C, Amin AN, Papadimitriou JC, Weir MR, Coughlin TR. Cyclosporine nephrotoxicity and dermal vascular alterations in renal transplants. Transplant Proc 1989; 21:1508-1510.

  33. Weir MR, Vlachkis ND, DeQuattro V, Douglas J, Svetkey LP, Singh S, Wiedl SC, Chen CF, Woodward DL, Saunders E. Evaluation of the clinical pharmacology of nilvadipine in patients with mild to moderate essential hypertension. J Clin Pharmacol 1990;30:425-437.

  34. Burris JF, Weir MR, Oparil S, Weber M, Cady WJ. An innovative approach to clinical trials of combination therapy: multifactorial assessment of diltiazem and hydrochlorothiazide in hypertension. JAMA 1990;263:1507-1512.

  35. Burris JF, Weir MR, Oparil S, Weber M, Cady WJ, Stewart WH. An assessment of diltiazem and hydrochlorothiazide in hypertension. Application of factorial trial design to a multicenter clinical trial of combination therapy. Comment in: JAMA 1990;264:971-973.

  36. Saunders E, Weir MR, Kong BW, et al. A comparison of the efficacy and safety of a -blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks. Arch Intern Med 1990;150:1707-1713.

  37. Croog SH, Kong BW, Levine S, Weir MR, Baume RM, Saunders E. Hypertensive black men and women. Quality of life and effects of antihypertensive medications. Black Hypertension Quality of Life Multicenter Trial Group. Arch Intern Med 1990;150:1733-1741.

  38. Weir MR, Klassen DK, Shen SY, Sullivan D, Buddemeyer EU, Handwerger BS. Acute effects of intravenous cyclosporine on blood pressure, renal hemodynamics, and urine prostaglandin production of healthy humans. Transplantation 1990;49:41-47.

  39. Plaisance KI, Drusano GL, Forrest A, Weir MR, Standiford HC. Effect of renal function on the bioavailability of ciprofloxacin. Antimicrobial Agents and Chemotherapy 1990;34:1031-1034.

  40. Weir MR. Calcium channel blockers in organ transplantation: Important new therapeutic modalities. J Am Soc Nephrol 1990;1:S28-S38.

  41. Li XW, Weir MR. Radix Tripterygium Wilfordii–a Chinese herbal medicine with potent immunosuppressive properties. Transplantation 1990;50:82-86.

  42. Gottlieb SS, Weir MR. Renal effects of angiotensin-converting enzyme inhibition in congestive heart failure. Am J Cardiol 1990;66:14D-20D; discussion 20D-21D.

  43. Weir MR, Cassidy CA, Hall PS, Lancaster A, Schubert C, Urick A, Saunders E, Kong BW, Jenkins P, Lavin PT. Efficacy and tolerability of enalapril and sustained-release verapamil in older patients with mild to moderate essential hypertension. Clin Ther 1990;12:139-148.

  44. Weir MR. Mycobacterium tuberculosis: a disease of growing importance in urban population groups. NY State J Med 1990;90:585-586. Comment in: N Y State J Med 1990; 90:588-591.

  45. Weir MR, Peppler R, Gomolka D, Handwerger BS. Additive inhibition of afferent and efferent immunological responses of human peripheral blood mononuclear cells by verapamil and cyclosporine. Transplantation 1991;51:851-857

  46. Weir MR, Josselson J, Ekelund LG, Korc M, Pool JL, Stein GH, Wohlbach RA, Champion D. Nicardipine as antihypertensive monotherapy: positive effects on quality of life. J Hum Hypertens 1991;5:205-213.

  47. Weir MR, Klassen DK, Hall PS, Schubert C, Voss TE, Stromatt SC, Brown JA. Minimization of indomethacin-induced reduction in renal function by misoprostol. J Clin Pharm 1991;31:729-735.

  48. Muluk SC, Clerici M, Via CS, Weir MR, Kimmel PL, Shearer GM. Correlation of in vitro CD4+ T helper cell function with clinical graft status in immunosuppressed kidney transplant recipients. Transplantation 1991;52:284-291.

  49. Weir MR Impact of age, race, and obesity on hypertensive mechanisms and therapy. Am J Med 1991;90(5A):3S-14S.

  50. Weir MR. Therapeutic benefits of calcium channel blockers in cyclosporine-treated organ transplant recipients: blood pressure control and immunosuppression. Am J Med 1991; 90(5A):32S-36S.

  51. Weir MR, Li XW, Gomolka D, Peppler R, O'Bryan-Tear CG, Moran MA. The immunosuppressive properties of enisoprost and a 5-lipoxygenase inhibitor (SC-45662). Transplantation 1991;52:1053-1057.

  52. Muluk SC, Clerici M, Via CS, Weir MR, Kimmel PL, Shearer GM. A new approach for analysis of the mixed lymphocyte reaction that is predictive for human renal allograft rejection. Transplant Proc 1991:23; 1274-1276.

  53. Weir MR, Kong BW, Jenkins P, Lavin PT. Comparison of the efficacy and tolerability of lisinopril and sustained-release verapamil in black patients with hypertension. Clin Ther 1991; 13:409-416.

  54. Weir MR, Lavin PT. Comparison of the efficacy and tolerability of lisinopril and sustained-release verapamil in older patients. Clin Ther 1991; 13:401-408.

  55. Weir MR, Klassen DK, Burdick JF. A pilot study to assess the ability of an orally available selective thromboxane synthase inhibitor to improve renal function in cyclosporine-treated renal transplant recipients. J Am Soc Neph 1992; 2:1285-1290

  56. Weir MR, Bakris GL. Risk for renal injury in diabetic hypertensive patients. The physiologic basis for blood pressure control. Postgraduate Medicine 1992; 91(3): 77-80,83-84.

  57. Weir MR, Bakris GL. Risk for renal injury in diabetic hypertensive patients. Pharmacologic approaches. Postgraduate Medicine 1992; 91(3):87-91,94-95.

  58. Gottlieb SS, Robinson S, Weir MR, Fisher ML, Krichten CM. Determinants of the renal response to ACE inhibition in patients with congestive heart failure. Am Heart J 1992; 124:131-136.

  59. Burnett HW, Friedman R, Perell F, Weir MR, Klassen DK. The impact of chronic corticosteroid administration on intraocular pressure in renal transplant recipients. J Clin Transplantation 1992; 6:199-201.

  60. Weir MR, Weber MA, Punzi HA, Serfer HM, Rosenblatt S, Cady WJ. A dose escalation trial comparing the combination of diltiazem SR and hydrochlorothiazide with the monotherapies in patients with essential hypertension. J Hum Hypertens 1992;6:133-138.

  61. Felicetta JV, Serfer HM, Cutler NR, Comstock TJ, Huber GL, Weir MR, Hafner K, Park GD. A dose-response trial of once-daily diltiazem. Am Heart J 1992; 123:1022-1026.

  62. Weir MR, Peppler R, Gomolka D, Handwerger BS. Evidence that the antiproliferative effect of verapamil on afferent and efferent immune responses is independent of calcium channel inhibition. Transplantation 1992; 54:681-685.

  63. Weir MR. Hypertensive nephropathy: is a more physiologic approach to blood pressure control an important concern for the preservation of renal function? Am J Med 1992; 93(2A): 27S-37S.

  64. Klassen DK, Weir MR, Buddemeyer EU. Simultaneous measurements of glomerular filtration rate by two radioisotopic methods in patients without renal impairment. J Am Soc Neph 1992; 3:108-112.

  65. Weir MR, Wright JT Jr., Ferdinand KC, Cook CA, Champion D, Wong S, Jenkins PA, Kong BW. Comparison of the efficacy and metabolic effects of nicardipine and hydrochlorothiazide in hypertensive black men and women. J Hum Hypertens 1993; 7:141-147.

  66. Weir MR, Peppler R, Gomolka D, Handwerger BS. Calcium channel blockers inhibit cellular uptake of thymidine, uridine, and leucine: the incorporation of these molecules into DNA, RNA and protein in the presence of calcium channel blockers is not a valid measure of lymphocyte activation. Immunopharmacology 1993; 25:75-82.

  67. Weir MR, Bakris GL. Albuminuria in hypertensive diabetics: Is it an important variable in treatment? Postgraduate Medicine 1993;92(S):23-32.

  68. Weir MR, Tuck ML. Essential hypertension in blacks: is it a metabolic disorder? AJKD 1993; 21(Suppl 1):58-67.

  69. Schulick RD, Weir MR, Miller MW, Cohen DJ, Bermas BL, Shearer GM. Longitudinal study of in vitro CD4+ T helper cell function in recently transplanted renal allograft patients undergoing tapering of their immunosuppressive drugs. Transplantation 1993;56:590-596.

  70. Weir MR, Fagan T, Chrysant S, Flamenbaum W, Kaihlanen PM, Leug M, Anzalone D. Comparison of the efficacy and tolerability of an angiotensin converting enzyme inhibitor (lisinopril) versus a calcium channel antagonist (diltiazem SR) in the treatment of moderate to severe hypertension. J Hum Hypertens 1994; 8:531-537.

  71. Riley DJ, Weir MR, Bakris GL. Renal adaptation to the failing heart. Understanding the cascade of responses. Postgraduate Med 1994; 95:141-146,149-150.

  72. Riley DJ, Weir MR, Bakris GL. Renal adaptation to the failing heart. Avoiding a therapeutic misadventure. Postgraduate Med 1994;95:153-156.

  73. Schulick RD, Muluk SC, Clerici M, Bermas BL, Via CS, Weir MR, Shearer GM. Value of in vitro CD4+ T helper cell function test for predicting long-term loss of human renal allografts. Transplantation 1994; 57:480-482.

  74. Weir MR. Speed and duration of dose titration with the angiotensin converting enzyme inhibitor quinapril: relationship with efficacy in patients with moderate hypertension. J Hum Hypertens 1994; 8:725-730.

  75. Simpson LL, Standley PR, Zhang F, Ram JL, Weir MR, Sowers JR. Role of calcium in vascular smooth muscle proliferation: antiproliferative effects of verapamil enantiomers in vascular smooth muscle cells. J Vasc Biol Med 1994

  76. Weir MR, Suthanthiran M. Supplementation of immunosuppressive regimens with calcium channel blockers: rationale and clinical efficacy. Clinical Immunother 1994; 2:458-467.

  77. Weir MR, Messerli, FH. Optimal titration of ACE inhibitors. J Hum Hypertens 1994;8:153-162.

  78. Hoelscher DD, Weir MR, Bakris GL. Hypertension in diabetic patients: an update of interventional studies to preserve renal function. J Clin Pharmacol 1995; 35:73-80.

  79. Weir MR. Diltiazem: ten years of clinical experience in the treatment of hypertension. J Clin Pharm 1995;35:220-232.

  80. Houston MC, Weir MR, Gray J, Ginsberg D, Szeto C, Kaihlenen PM, Sugimoto D, Runde M. The effects of nonsteroidal anti-inflammatory drugs on blood pressures of patients with hypertension controlled by verapamil. Arch Int Med 1995;155:1049-1054.

  81. Weir MR. Salt intake and hypertensive renal injury in African-Americans: a therapeutic perspective. Am J Hypertens 1995;8(6): 635-644.

  82. Weir MR, Dengel DR, Behrens MT, Goldberg AP. Salt-induced increases in systolic blood pressure affect renal hemodynamics and proteinuria. Hypertension 1995; 25:1339-1344.

  83. Prisant LM, Weir MR, Papademetriou V, Weber MA, Adegbile IA, Alemayehu D, Lefkowitz MP, Carr AA. Low-dose drug combination therapy: an alternative first-line approach to hypertension treatment. Am Heart J 1995;130:359-366.

  84. Moy E, Bartman BA, Weir MR. Access to hypertensive care. Effects of income, insurance, and source of care. Arch Intern Med 1995;155:1497-1502.

  85. Weir MR, Gray JM, Paster R, Saunders E. Differing mechanisms of action of angiotensin-converting enzyme inhibition in black and white hypertensive patients. The Trandolapril Multicenter Study Group. Hypertension 1995; 26(1):124-130.

  86. Weir MR. Pharmacologic antagonism of the renin-angiotensin-aldosterone system: a focus on angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists. Cardiovascular Reviews and Reports 1995;9:37-42.

  87. Frishman WH, Burris JF, Mroczek WJ, Weir MR, Alemayehu D, Simon JS, Chen SY, Bryzinski BS. First-line therapy option with low-dose bisoprolol fumarate and low-dose hydrochlorothiazide in patients with stage I and stage II systemic hypertension. Journal of Clinical Pharmacology 1995; 35(2):182-188.

  88. Weir MR, Hanes DS. Hypertension in African Americans: a paradigm of metabolic disarray. Seminars in Nephrology 1996;16(2):102-109.

  89. Pirsch JD, Andrews C, Hricik DE, Josephson MA, Leichtman AB, Lu CY, Melton LB, Rao VK, Riggio RR, Stratta RJ,Weir MR,. Pancreas transplantation for diabetes mellitus. AJKD 1996; 27(3):444-450.

  90. Weir MR, Berger ML, Weeks ML, Liss CL, Santanello NC. Comparision of the effects on quality of life and of the efficacy and tolerability of lovastatin versus pravastatin. The Quality of Life Multicenter Group. Am J Cardiol 1996;77:475-479.

  91. Klassen DK, Hoehn-Saric EW, Weir MR, Papadimitriou JC, Drachenberg CB, Johnson LB, Schweitzer EJ, Bartlett ST. Isolated pancreas rejection in combined kidney pancreas transplantation: results of percutaneous pancreas biopsy. Transplantation 1996; 61:974-977.

  92. Weir MR, Sugimoto D, Gray J, Black H, Saunders E, Applegate W, Davidson J, Ginsberg D, Marbury T, Moser M, Cziner D, deSilva J, Mills D, Rosenblum J, Hall WD. Safety and efficacy of once-daily captopril plus hydrochlorothiazide versus nifedipine gastrointestinal therapeutic system in black patients with mild to moderate hypertension. Am J Therapeutics 1996;3:811-817.

  93. Weir MR, Prisant LM, Papademetriou V, Weber MA, Adegbile IA, Alemayehu D, Lefkowitz MP. Antihypertensive therapy and quality of life: influence of blood pressure reduction, adverse events, and prior antihypertensive therapy. Am J Hypertens 1996;9:854-859.

  94. Walker JA, Klassen DK, Hooper FJ, Hoehn-Saric EW, Schweitzer EJ, Johnson LB, Bartlett ST, Weir MR. Late pancreas allograft rejection. Preliminary experience with factors predisposing to rejection. Transplantation 1996;62:539-543.

  95. Franklin SS, Weir MR, Smith DHG, Codispoti J, Stokes A, McNally C, Weber MA. Combination treatment with sustained-release verapamil and indapamide in the treatment of mild-to-moderate hypertension. Am J Therapeutics 1996; 3:506-514.

  96. Weir MR. Angiotensin-II receptor antagonists: a new class of antihypertensive agents. American Family Physician 1996;53:589-594.

  97. Hanes DS, Nicholson PG, Raval DD, Behrens MT, Weir MR. A cross-over comparison of the efficacy and safety of lovastatin and gemfibrozil in the treatment of hyperlipidemic organ transplant recipients. Am J Therapeutics 1996; 3:1-7.

  98. Johnson LB, Kuo PC, Dafoe DC, Schweitzer EJ, Alfrey EJ, Klassen DK, Hoehn-Saric EW, Weir MR, Bartlett ST. Double adult renal allografts: a technique for expansion of the cadaveric kidney donor pool. Surgery 1996; 120:580-583.

  99. Schweitzer EJ, Drachenberg CB, Anderson L, Papadimitriou JC, Kuo PC, Johnson LB, Klassen DK, Hoehn-Saric EW, Weir MR, Bartlett ST. Significance of the Banff borderline biopsy. AJKD 1996; 28(4);585-588

  100. Malinow L, Walker J, Klassen D, Oldach D, Schweitzer E, Bartlett ST, Weir MR. Antilymphocyte induction immuno-suppression in the post-Minnesota anti-lymphocyte globulin era: incidence of renal dysfunction and delayed graft function. A single center experience. Clin Transplantation 1996;10(3):237-242.

  101. Weir MR. Differing effects of antihypertensive agents on urinary albumin excretion. American Journal of Nephrology 1996; 16(3):237-245.

  102. Dengel DR, Goldberg AP, Mayuga RS, Kairis GM, Weir MR. Insulin resistance, elevated glomerular filtration fraction, and renal injury. Hypertension 1996; 28(1):127-132.

  103. Bakris GL, Weir MR. Salt intake and reductions in arterial pressure and proteinuria: Is there a direct link? Am J Hypertens 1996; 9:200S-206S.

  104. Weir MR. Insulin resistance and salt sensitivity: A renal hemodynamic abnormality? Am J Hypertens 1996; 9:193S-199S.

  105. Johnson LB, Kuo PC, Schweitzer EJ, Ratner LE, Klassen DK, Hoehn-Saric EW, de la Torre A, Weir MR, Strange J, Bartlett ST. Double renal allografts successfully increase utilization of kidneys from older donors within a single organ procurement organization. Transplantation 1996;62(11):1581-1583.

  106. Bartlett ST, Schweitzer EJ, Johnson LB, Kuo PC, Papadimitriou JC, Drachenberg CB, Klassen DK, Hoehn-Saric EW,Weir MR,, Imbembo AL. Equivalent success of simultaneous pancreas kidney and solitary pancreas transplantation. A prospective trial of tacrolimus immunosuppression with percutaneous biopsy. Ann Surg 1996;224:440-449; discussion 449-452.

  107. Sowers JR, Weir MR. Introduction: a reappraisal of therapeutic issues in hypertension. Am J Med 1996;101(suppl 3A):1S-2S.

  108. Hanes DS, Weir MR, Sowers JR. Gender considerations in hypertension pathophysiology and treatment. Am J Med 1996;101(suppl 3A):10S-21S.

  109. Bakris GL, Weir MR, Sowers JR. Therapeutic challenges in the obese diabetic patient with hypertension. Am J Med 1996; 101(suppl 3A):33S-46S.

  110. Weir MR, Flack JM, Applegate WB. Tolerability, safety, and quality of life and hypertensive therapy: the case for low-dose diuretics. Am J Med 1996;101(suppl 3A):83S-92S.

  111. Drachenberg CB, Papadimitriou JC, Weir MR, Klassen DK, Hoehn-Saric E, Bartlett ST. Histologic findings in islets of whole pancreas allografts: lack of evidence for recurrent cell-mediated diabetes mellitus. Transplantation 1996;62:1770-1772.Weir MR,. Can hypertension be prevented? Is salt reduction important in hypertension? Ethnicity & Disease 1996;6:321-325.

  112. Weir MR, Elkins M, Liss C, Vrecenak AJ, Barr E, Edelman JM. Efficacy, tolerability, and quality of life of losartan, alone or with hydrochlorothiazide, versus nifedipine GITS in patients with essential hypertension. Clin Ther 1996; 18(3):411-428.

  113. Weir MR. The calcium channel blocker debate: Dr. Weir’s opinion. J Myocardial Ischemia 1996; 8:129-130.

  114. Drachenberg CB, Klassen DK, Bartlett ST, Hoehn-Saric EW, Schweitzer EJ, Johnson LB, Weir MR, Papadimitriou JC. Histologic grading of pancreas acute allograft rejection in percutaneous needle biopsies. Transplant Proc 1996 ;28:512-513.

  115. Papadimitriou JC, Drachenberg CB, Anderson L, Bartlett ST, Johnson LB, Klassen DK, Hoehn-Saric EW, Weir MR, Schweitzer EJ. Follow-up of patients with borderline changes in renal allograft biopsies: clinical outcome and evaluation of other histological features in addition to tubulitis. Transplant Proc 1996; 28:517-518.

  116. Schweitzer EJ, Anderson L, Kuo PC, Johnson LB, Klassen DK, Hoehn-Saric EW, Weir MR, Bartlett ST. Safe pancreas transplantation in patients with coronary artery disease. Transplantation 1997; 63:1294-1299.

  117. Schweitzer EJ, Yoon S, Hart J, Anderson L, Barnes R, Evans D, Hartman K, Jaekels J, Johnson LB, Kuo PC, Hoehn-Saric EW, Klassen DK, Weir MR, Bartlett ST. Increased living donor volunteer rates with a formal recipient family education program. AJKD 1997;29:739-745.

  118. Weir MR. The influence of dietary salt on the antiproteinuric effect of calcium channel blockers. AJKD 1997; 29:800-805.

  119. Reisin E, Weir MR, Falkner B, Hutchinson HG, Anzalone DA, Tuck ML. Lisinopril versus hydrochlorothiazide in obese hypertensive patients: a multicenter placebo-controlled trial. Hypertension 1997; 30:140-145.

  120. Kuo PC, Johnson LB, Schweitzer EJ, Klassen DK, Hoehn-Saric EW, Weir MR, Drachenberg CB, Papadimitriou JC, Bartlett ST. Solitary pancreas allografts. The role of percutaneous biopsy and standardized histologic grading of rejection. Arch Surg 1997; 132:52-57.

  121. Massie BM, Chrysant SG, Jain A, Weir MR, Weiss R, Kobrin I. Antihypertensive effects of mibefradil: a double-blind comparison with diltiazem CD. Clin Cardiol 1997; 20:562-568.

  122. Drachenberg CB, Papadimitriou JC, Klassen DK, Racusen LC, Hoehn-Saric EW, Weir MR, Kuo PC, Schweitzer EJ, Johnson LB, Bartlett ST. Evaluation of pancreas transplant needle biopsy: reproducibility and revision of histologic grading system. Transplantation 1997; 63:1579-1586.

  123. Weir MR. Population characteristics and the modulation of the renin-angiotensin system in the treatment of hypertension. J Hum Hypertens 1997; 11:17-21.

  124. Weir MR, Hall PS, Behrens MT, Flack JM. Salt and blood pressure responses to calcium antagonism in hypertensive patients. Hypertension 1997; 30:422-427.

  125. Dengel DR, Mayuga RS, Kairis GM, Goldberg AP, Weir MR. Effect of dietary sodium on insulin sensitivity in older, obese, sedentary hypertensives. Am J Hypertens 1997 10:964-970.

  126. Messerli FH, Schmieder RE, Weir MR. Salt: a perpetrator of hypertensive target organ disease? Arch Int Med 1997; 57:2449-2452.

  127. Schweitzer EJ, Yoon S, Fink J, Wiland A, Anderson L, Kuo PC, Lim JW, Johnson LB, Farney AC, Weir MR, Bartlett ST. Mycophenolate mofetil reduces the risk of acute rejection less in African-American than in Caucasian kidney recipients. Transplantation 1998; 65:242-248.

  128. Chrysant SG, Weir MR, Weder AB, McCarron DA, Canossa-Terris M, Cohen JD, Mennella RF, Kirkegaard LW, Lewin AJ, Weinberger MH. There are no racial, age, sex, or weight differences in the effect of salt on blood pressure in salt-sensitive hypertensive patients. Arch Int Med 1997; 157:2489-2494.

  129. Weir MR. Non-diuretic-based antihypertensive therapy and potassium homeostasis in elderly patients. Coronary Artery Disease 1997; 8:499-504.

  130. Weir MR. Hypertension in elderly African-Americans. Am J Geri Cardiol 1997; 6:13-20.

  131. Weir MR, Anderson L, Fink JC, Gabregiorgish K, Schweitzer EJ, Hoehn-Saric E, Klassen DK, Cangro CB, Johnson LB, Kuo PC, Lim JY, Bartlett ST. A novel approach to the treatment of chronic allograft nephropathy. Transplantation 1997; 64:1706-1710.

  132. Weir MR, Saunders E for the Trandolapril Multicenter Study Group. Renin status does not predict the anti-hypertensive response to angiotensin-converting enzyme inhibition in African-Americans. J Human Hypertens 1998; 12:189-194.

  133. Pool JL, Guthrie RM, Littlejohn TW III, Raskin P, Shephard AMM, Weber MA, Weir MR, Wilson TW, Wright J, Kassler-Taub KB, Reeves RA. Dose-related antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension. Am J Hypertens 1998; 11:462-470.

  134. Weir MR, Chrysant SG, McCarron DA, Canossa-Terris M, Cohen JD, Gunter PA, Lewin AJ, Mennella RF, Kirkegaard LW, Hamilton JH, Weinberger MH, Weder AB. Influence of race and dietary salt on the antihypertensive efficacy of an angiotensin-converting enzyme inhibitor or a calcium channel antagonist in salt-sensitive hypertensives. Hypertension 1998; 31:1088-1096.

  135. Weir MR, Reisin E, Falkner B, Hutchinson HG, Sha L, Tuck ML, for the Trophy Study Group. Nocturnal Reduction of Blood Pressure and the Antihypertensive Response to A Diuretic or Angiotensin Converting Enzyme Inhibitor in Obese Hypertensive Patients. Am J of Hypertens 1998; 11(8) Part I:914-920.

  136. Weir MR, Dworkin LD. Antihypertensive Drugs, Dietary Salt, and Renal Protection: How low should you go and with which therapy? AJKD 1998; 32(1):1-22.

  137. Bakris GL, Weir MR, DeQuattro V, McMahon FG. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int 1998; 54:1283-1289.

  138. Prisant LM, Neutel JM, Papademetriou V, DeQuattro V, Hall WD, Weir MR. Low-dose combination treatment for hypertension versus single-drug treatment-bisoprolol/hydrochlorothiazide versus amlodipine, enalapril, and placebo: Combined analysis of comparative studies. American Journal of Therapeutics 1998; 5:313-321.

  139. Weir MR. The rationale for combination versus single-entry therapy in hypertension. American Journal of Hypertension 1998:11:163S-169S.

  140. Papadimitriou JC, Drachenberg CB, Wiland A, Klassen DK, Fink J, Weir MR, Cangro C, Schweitzer EJ, Bartlett ST. Histologic grading of acute allograft rejection in pancreas needle biopsy. Transplantation 1998; 66:1741-1745.

  141. Weir MR,Tolchin N, Toth P, Reeves RA. Addition of hydrochlorothiazide to irbesartan produces further dose-related reductions in blood pressure within two weeks. J Hypertens 1998; 16(suppl 2):S130.

  142. Weir, MR. Impact of salt intake on blood pressure and proteinuria in diabetes: Importance of the renin-angiotensin system. Miner and Electrolyte Metab 1998; 24:438-445.

  143. Papademetriou V, Prisant LM, Neutel JM, Weir MR. Efficacy of low-dose combination of bisoprol/hydrochlorothiazide compared with amlodipine and enalapril in men and women with essential hypertension. Am J Cardiol 1998; 81:1363-1365.

  144. Weir MR. Obesity-related hypertension: Many factors affect response to Tx. Am J Hypertens 1998; 12:29-30.

  145. Weir MR, Fink JC. Risk for posttransplant diabetes mellitus with current immunosuppressive medications. Am J Kidney Disease 1999 34 (1): 1-13.

  146. Prisant LM, Weir MR, Frishman WH, Neutel JM, Davidov ME, Lewin AJ. Self reported sexual dysfunction in men and women treated with bisoprolol, hydrochlorothiazide, enalapril, amlodipine, placebo, or bisoprolol/hydrochlorothiazide. J Clin Hypertension 1999:1(1)22-26.

  147. Weir MR. How low should we treat blood pressure and why? J Clin Hypertens 1999; 1:199-208.

  148. Jacobs S, Cho E, Philosophe B, Bartlett ST, Weir MR. A Comparison of recipient renal outcomes with laparoscopic versus open live donor nephrectomy. J Urol; 2004, 162:963-964.

  149. Prisant LM, Neutel JM, Ferdinand K, Papademetriou V, DeQuattro V, Hall WD, Weir MR. Low-dose combination therapy as first-line hypertension treatment for blacks and nonblacks. J Natl Med Assoc 1999;91:40-48.

  150. Drachenberg CB, Papadimitriou JC, Klassen DK, Weir MR, Cangro CB, Fink JC, Bartlett ST. Chronic pancreas allograft rejection: morphologic evidence of progression in needle biopsies and proposal of a grading scheme. Transplant Proc. 1999; 31:(1-2)614.

  151. Weir MR, Fink JC, Hanes DS, Gardner J, Klassen DK, Cangro, Schweitzer E, Bartlett ST. Chronic allograft nephropathy: effect of cyclosporine reduction and addition of mycophenolate mofetil on progression of renal disease. Transplant Proceedings, 1999; 31:1296-1287.

  152. Nogueira JM, Cangro CB, Fink JC, Klassen DK, Gardner J, Schweitzer E, Wiland A, Flowers J, Jacobs S, Cho E, Philosophe B, Bartlett ST, Weir MR. A comparison of recipient renal outcomes with laparoscopic versus open live donor nephrectomy. Transplantation 1999; 67:722-728.

  153. Hadley GA, Rostapshova EA, Gomolka DM, Taylor BM, Bartlett ST, Drachenberg CI, Weir, MR. Regulation of the epithelial cell-specific integrin, CD103, by human CD8+ cytolytic T lymphocytes. Transplantation 1999; 67(11)1418-1425.

  154. Weir MR and Fink JC. Post-transplant Diabetes Mellitus: risks versus benefits with current immunosuppressive medications. Am J Kidney Dis 1999 34:1-14

  155. Drachenburg CB, Beskow CO, Cangro CB, Bourquin PM, Simsir A, Fink J, Weir, MR, Klassen DK, Bartlett ST, Papadimitriou JC. Human Polyoma Virus in Renal Allograft Biopsies: Morphological findings and correlation with urine cytology. Human Pathology 1999:30(8)970-977

  156. Drachenberg CB, Klassen DK, Weir, MR, Wiland A, Fink JC, Bartlett ST, Cangro CB, Blahut S, Papadimitriou JC. Islet cell damage associated with tacrolimus and cyclosporine: morphological features in pancreas allograft biopsies and clinical correlation. Transplantation 1999; 68(3)396-402.

  157. Weir MR. Are drugs that block the renin-angiotensin system effective and safe in patients with renal insufficiency? Am J Hypertens 1999;12:195S-203S.

  158. Weir MR, Dzau VJ. The renin-angiotensin-aldosterone system: a specific target for hypertension management. Am J Hypertens 12:1999:205S-213S.

  159. Weir MR. Diabetes and hypertension: Blood pressure control and consequences. Am J Hypertension 1999:12(12):170S-178S.

  160. Papadimitriou JC, Drachenberg CB, Wiland A, Klassen DK, Fink J, Weir MR, Cangro C, EJ Schweitzer, Bartlett ST. Histologic grading of acute allograft rejection in pancreas needle biopsy. Transplantation, 1999; 66:1741-1745.

  161. Weir MR. Effects of low dose combination therapy with amlodipine/benazepril on systolic blood pressure. Cardiovascular Review and Reports 1999; 20(7)368-374.

  162. Weir MR. Indicators and treatment of hypertensive heart disease. Hospital Practice 1999; 34 (9):93-107.

  163. Weir MR. Hypertension: Goal systolic and diastolic blood pressure. Current Hypertension Reports 1999:1:411-413.

  164. Wali RK, Weir MR. Hypertensive cardiovascular disease in African Americans. Current Hypertension Reports: 1999 (6)521-528.

  165. Weir MR. The role of multiple drug therapy for controlling hypertension in African Americans. J Clin Hyperten 2000; 2:99-108,123

  166. Weir MR, Bravo E, Robinson J, Harris S, Hardison JD, Michelson EL, Wang R for the ACTION Investigators. Effects of candesartan cilexetil alone or as add-on therapy in African-American patients with hypertension: a large clinical experience trial. Ethinicity & Disease 2000:10:298.

  167. Weir MR, Smith DHG, Neutel JH, Bedigian MP. Valsartan alone and in combination with other antihypertensives on blood pressure control in African-American patients receiving a high salt diet. Ethnicity & Disease 2000:10:316.

  168. Weir MR, Moser M. Diuretics and beta-blockers: is there a risk for dyslipidemia? Am Heart J 2000; 139:174-183.

  169. Weir MR, Maibach EW, Bakris GL, et al. Implications of a health lifestyle and medication analysis for improving hypertension control. Arch Intern Med 2000; 160(4):481-490.

  170. Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: Is this a cause for concern? Arch Intern Med 2000; 160:685-693.

  171. Hjelmesaeth J, Hartmann A, Fink JC, Weir MR. Risk for posttransplant diabetes mellitus with current immunosuppressive medications. Letter to the editor
1   2   3   4   5   6   7


The database is protected by copyright ©dentisty.org 2016
send message

    Main page